Decibel Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Laurence Reid

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage	44.5%
CEO tenure	3.8yrs
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

CEO Compensation Analysis

How has Laurence Reid's remuneration changed compared to Decibel Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$62m
Dec 31 2022	US$1m	US$548k	-US$63m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$801k	US$522k	-US$54m
Sep 30 2021	n/a	n/a	US$576k
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	US$8m
Dec 31 2020	US$4m	US$574k	US$7m

Compensation vs Market: Laurence's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD738.70K).

Compensation vs Earnings: Laurence's compensation has increased whilst the company is unprofitable.

CEO

Laurence Reid (59 yo)

3.8yrs

Tenure

US$1,232,276

Compensation

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laurence Reid	President & CEO	3.8yrs	US$1.23m	no data
Anna Trask	Executive VP & Chief People Officer	5.8yrs	US$618.23k	0% $ 0
John Lee	Executive VP & Chief Development Officer	7.1yrs	US$733.16k	0% $ 0
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
James Murphy	Interim CFO	less than a year	no data	no data
Elaine Cope	Vice President of Operations	2.1yrs	no data	no data
Geoff Horwitz	VP of Corporate Development & Head of Business Development	less than a year	no data	no data
Vassili Valayannopoulos	VP and Head of Clinical Research & Development	less than a year	no data	no data

2.1yrs

Average Tenure

65yo

Average Age

Experienced Management: DBTX's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Glenn Pierce	Member of Scientific Advisory Board	2.4yrs	no data	no data
Constance Cepko	Member of Scientific Advisory Board	2.4yrs	no data	no data
Guangping Gao	Member of Scientific Advisory Board	2.4yrs	no data	no data
Alan Cheng	Member of Scientific Advisory Board	no data	no data	no data
David Ginty	Member of Scientific Advisory Board	no data	no data	no data
Michael Greenberg	Member of Scientific Advisory Board	no data	no data	no data
Dwight Bergles	Member of Scientific Advisory Board	no data	no data	no data
Matthew Kelley	Member of Scientific Advisory Board	2.4yrs	no data	no data

2.4yrs

Average Tenure

68yo

Average Age

Experienced Board: DBTX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Decibel Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Decibel Therapeutics, Inc. Announces Board Changes

High number of new directors

High number of new directors

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics, Inc. Announces Executive Changes

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age